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Objective: This study aims to assess the role of the internal iliac node (IIN) dissection, which is occasionally neglected in
radical hysterectomy for uterine cervical cancer.
Methods: We retrospectively reviewed the clinical and pathological records of patients with cervical cancer (stage IB1-IIB)
with lymph node metastases, who underwent radical hysterectomy at our institute. We assessed the number and site of lymph
node metastases along with history and site of recurrence.
Results: Twenty-three patients who underwent radical hysterectomy reported lymph node metastases and included in this
study. Of these, 13 with only one positive node revealed no IIN metastases, whereas 5 of 10 with two or more positive nodes
exhibited IIN metastases. While 20 patients, including 4 with positive IIN, received platinum-based chemotherapy, 3 received
radiotherapy as adjuvant therapy. Four patients, including 2 with positive IIN, experienced disease recurrence.
Conclusion: Given the high prevalence of IIN metastases in patients with multiple lymph node metastases, the IIN dissection
should be performed in radical hysterectomy. IIN metastasis could be one of the important factors for regional recurrence in
cervical cancer.
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Introduction
The number of patients with cervical cancer, especially
in younger generation, is increasing in the last two dec-
ades in Japan１）. Recently, fertility-sparing surgery, such
as radical trachelectomy, has gained recognition as treat-
ment strategies for early cervical cancer. Meanwhile,
lymph node metastasis has been established as one of the
crucial prognostic factors in early cervical cancer２）３）. In
the current clinical practice for early cervical cancer with
lymph node metastases, either primary concurrent
chemoradiotherapy (CCRT) or radical hysterectomy in-
corporating the systematic pelvic node dissection fol-
lowed by CCRT are applied. Although the lymph node
dissection is the best method to determine the nodal state,
its therapeutic role remains debatable. Conversely, multi-
modal therapy of node-positive cervical cancer by radical
surgery and (chemo) radiation correlates with the aug-
mented risk of severe toxicity, such as radiation colitis,
cystitis, or lymphedema. Recently, the European Society
of Gynaecological Oncology recommended that the com-
bination of radical surgery and radiotherapy as treatment
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Fig.　1　External iliac vessels and internal iliac vessels after sys-
tematic pelvic lymphadenectomy (right side). Arrow, the medial
internal iliac node region. 
InIA, internal iliac artery; InIV, internal iliac vein; ExIA, external 
iliac artery; ExIV, external iliac vein; DUV, deep uterine vein.
strategy should be avoided because of the highest associ-
ated morbidity４）. They recommended avoiding further
pelvic lymph node dissection and radical hysterectomy if
lymph node involvement is detected intraoperatively and
that these patients should be referred for definitive
CCRT.
Meanwhile, radical surgery followed by adjuvant che-
motherapy (with or without neoadjuvant chemotherapy:
NACT ) has emerged as a valid alternative treatment
strategy for node-positive patients with early cervical
cancer (stage IB1-IIB) in Europe, Latin countries, and Ja-
pan５）-９）. Höckel et al. reported excellent pelvic control and
overall survival rate for node-positive patients with cervi-
cal cancer with their modified radical hysterectomy and
lymph node dissection without adjuvant radiotherapy６）.
Angioli et al. reported the validity of adjuvant chemo-
therapy after NACT and radical hysterectomy as a treat-
ment strategy for node-positive patients with cervical
cancer７）.
However, recent retrospective research in Japan re-
ported that node-positive patients receiving adjuvant che-
motherapy following radical surgery were more suscepti-
ble to frequent local relapses compared with those receiv-
ing adjuvant CCRT１０）１１）. Perhaps, one possible factor of
pelvic control disadvantage of adjuvant chemotherapy
group could be incompleteness of the pelvic node dissec-
tion. Hypothetically, the anticancer drug distribution
along the lymphatic system might be obstructed after
lymphadenectomy. Consequently, cancer cells in the
missing residual lymph nodes easily escape from the at-
tack of chemotherapy agents. For example, the internal
iliac node (IIN), located along the internal iliac vessels, is
often neglected or abandoned for the pelvic node dissec-
tion. The blunt node dissection of this region often
causes annoying bleeding. As surgical procedures or
techniques have been passed on to younger generations
at each institute, the procedures and intensity of lymph
node dissection might vary among institutes. In addition,
the description of the medial IIN dissection is often miss-
ing in the Japanese literature or educational DVD con-
tents explaining the procedure of pelvic lymphadenec-
tomy for radical hysterectomy１２）１３）.
Thus, this study aims to elucidate the role of the IIN in
the therapeutic pelvic lymphadenectomy. The study ret-
rospectively investigates the clinical and pathological
data from node-positive patients with early cervical can-
cer who underwent radical hysterectomy at our institute.
Patients and Methods
We retrospectively examined the clinical and pathologi-
cal records of patients with cervical cancer, the Interna-
tional Federation of Gynecology and Obstetrics (FIGO)
stage IB1-IIB, with lymph node metastases, who under-
went radical hysterectomy between October 2007 and
December 2017 at our institute. The study was approved
by the institutional Research Ethics Committee ( No.
4407).
The Okabayashi-Fujii methods formed the basis of
radical hysterectomy １４）, although we preferred the
Höckel’s procedure for modified radical hysterectomy re-
garding the sacro-uterine ligament resection and hy-
pogastric nerve preservation１５）. Pelvic lymphadenectomy
with therapeutic intent was performed as described in the
Gynecologic Cancer Surgery by Morrow and Curtin１６）.
The medial IIN was cautiously removed from its connec-
tion with sacral nodes toward the lymphatic channels en-
tering the parametrium (Fig. 1). If node metastases were
suspected during surgery, frozen-section was performed
for confirmation. In node-positive cases, the node dissec-
tion area was extended to the paraaortic region up to the
level of the root of the inferior mesenteric artery, at least.
For patients with large tumor size (> 5 cm), 1 or 2 cy-
cles of NACT was administered preoperatively. Regard-
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Table　1　Patients’ characteristics
Factors (%)
Age Median: 45 (range 23-73) years
Clinical Stage
IB1 12 (52)
IB2  6 (26)
IIA1 1 (4)
IIA2 1 (4)
IIB  3 (13)
Histopathology
Squamous cell 15 (65)
Adenosquamous 2 (9)
Adenocarcinoma*  6 (26)
pT**
1b1  6 (26)
1b2  6 (26)
2a2 1 (4)
2b 10 (44)
pN (number) 
1 13 (56)
2 or more*** 10 (44)
pMA****  3 (13)
*Endocervical adenocarcinoma (usual type), 2 patients; 
mucinous carcinoma, 2 patients; endometrioid carcinoma, 
1 patient; and serous carcinoma, 1 patient.
**Including 6 patients with neoadjuvant chemotherapy 
(ypT).
***2: 3 patients, 3: 3 patients, 4: 3 patients, 9: 1 patient.
****Paraaortic lymphadenectomy was performed, up to 
the inferior mesenteric artery in 16 patients and up to the 
renal vein in 3 patients.
ing adjuvant therapy, we provided patients with informa-
tion on chemotherapy as well as (chemo) radiotherapy.
Patients could then choose between these two therapies.
Adjuvant therapy was administered within 4 weeks post-
operatively after obtaining written informed consent from
patients. Regarding NACT or adjuvant chemotherapy,
we administered irinotecan plus platinum agents every 4
weeks for squamous cell carcinoma and paclitaxel or do-
cetaxel plus platinum agents triweekly for non-squamous
cell carcinoma (1 to 2 cycles for NACT, and 5 to 6 cycles
for the postoperative adjuvant therapy, respectively). Ra-
diotherapy was given as whole-pelvis external irradiation
at 50 Gy, with or without weekly cisplatin administration
for 5 cycles.
In this study, we assessed the number and site of posi-
tive lymph nodes, site of recurrence, and the progression-
free survival (PFS). The nomenclature of the retroperito-
neal lymph nodes was determined by the classification by
the committee on the classification of regional lymph
nodes of the Japan Society of Clinical Oncology
( JSCO)１７）. The PFS was evaluated using the Kaplan-
Meier method.
Results
Between October 2007 and December 2017, 67 patients
with FIGO stage IB1-IIB cervical cancer underwent radi-
cal hysterectomy at our institute. Of these, 24 patients ex-
hibited lymph node metastases. We excluded 1 patient
with small-cell carcinoma because of its histological
specificity; thus, 23 (median age 45 years) patients were
enrolled in this study. Table 1 summarizes the character-
istics of node-positive patients in this study. Of all, 12
patients (52%) had stage IB1 cancer, whereas 3 had stage
IIB cancer. While 15 patients (65%) had squamous cell
carcinoma, the remaining 8 were diagnosed with other
histological types. Six patients received 1 or 2 cycles of
NACT. While 13 patients (54%) had solitary node metas-
tasis, 10 had 2 or more node metastases. Paraaortic lym-
phadenectomy was performed, up to the inferior mesen-
teric artery in 16 patients and up to the renal vein in 3 pa-
tients; of these, 3 patients had paraaortic node metastases.
In this study, the median number of pelvic nodes re-
moved was 41 (range 25-64). Regarding the distribution
of pelvic node metastasis, solitary node metastasis was
detected in the obturator node in 6 patients, external iliac
node in 5 patients, parametrial node in 1 patient, and
common iliac node in 1 patient. We found no IIN metas-
tasis in 13 patients with solitary node metastasis. Regard-
ing patients with multiple node metastases, metastases
were detected in the obturator node in 7 patients, external
iliac node in 6 patients, IIN in 5 patients, sacral node in 1
patient, and suprafemoral node in 1 patient (Table 2).
Twenty patients, including 4 with positive IIN, re-
ceived platinum-based chemotherapy, and 3 received ra-
diotherapy as adjuvant therapy. The median follow-up
period for censored patients was 86 ( range 8-127 )
months. Disease recurrence was experienced by 4 pa-
tients, including 2 with positive IIN; these 2 patients with
positive IIN had mucinous histology and relapsed with
dissemination into the peritoneum and pelvic cavity de-
spite adjuvant chemotherapy. The other 3 patients with
positive IIN ( 2 with squamous cell type and 1 with
adenosquamous type) have presented no evidence of dis-
ease to date (Table 3). The other 2 relapsed patients were
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Fig.　2　The progression-free survival of node-positive patients
with adjuvant chemotherapy. The median follow-up, 86 (range 10-
118) months.
Table　2　The number of patients by the site of lymph node metastases (median number of pelvic 
nodes removed, 41 [range 25-64])
The number of patients
Patients with a solitary positive node 
(13 patients)
Patients with 2 or more positive nodes 
(10 patients)
Parametrial node 1 0
Obturator node 6 7
External iliac node 5 6
Internal iliac node 0 5
Common iliac node 1 0
Sacral node 0 1
Suprafemoral node 0 1
Paraaortic node 0 3
Table　3　Patients with internal iliac node metastasis
No Stage/pT Histology
Number of 
positive node 
(Pelvic/PA)
Adjuvant 
therapy Rec First site of Rec Outcome
1 IB2/ yT1b2 Mucinous 3 /1 Chemo Yes Regional, IP 23 M
DOD
2 IB1/ T2b Mucinous 3 /0 Chemo Yes IP 8 M
DOD
3 IB2/ T1b2 Squamous 6 /3 Chemo/Rad* No - 102 M
NED
4 IB1/ T2b AdSq 3 /0 Chemo No - 57 M
NED
5 IB1/ T1b1 Squamous 4 /0 CCRT No - 8 M
NED
*External-beam radiation to the paraaortic region.
PA, paraaortic; Rec, recurrence; Chemo, chemotherapy; Rad, radiation; CCRT, concurrent chemoradiothera-
py; IP, intraperitoneal dissemination; AdSq, adenosquamous; M, months; DOD, died of disease; NED, no ev-
idence of disease.
diagnosed with squamous cell type and relapsed with dis-
semination (1 with adjuvant radiotherapy) and vaginal re-
currence (1 with adjuvant chemotherapy), respectively.
Figure 2 shows the PFS of 20 patients with positive
nodes who received adjuvant chemotherapy; their 5-year
PFS was 84.4%.
Discussion
This study focused on the IIN dissection in radical hys-
terectomy for cervical cancer and offered the following
suggestions. First, the IIN is at risk and frequently in-
volved in multiple nodal metastases; thus, metastasis to
this area might be one of the important factors for re-
gional recurrence in cervical cancer. Second, the com-
plete regional node dissection, including the IIN, in radi-
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cal hysterectomy might contribute not only to adequate
local control but also to disease-free benefit without adju-
vant radiotherapy, at least, in squamous-type cervical
cancer.
In this study, 13 patients with solitary positive node re-
vealed no IIN metastases, whereas 5 of 10 patients with
multiple positive nodes revealed IIN metastases. Previ-
ously, several studies have reported the distribution pat-
tern of pelvic node metastasis in patients with cervical
carcinoma treated with radical hysterectomy. Panici et al.
reported solitary metastasis in the obturator, external
iliac, or common iliac nodes. They detected IIN metasta-
sis in 5 (9.6%), all of whom had multiple node metasta-
ses, of 52 node-positive patients１８）. Our results corrobo-
rate with that of Panici et al., although the positive rate of
IIN was higher. Sakuragi et al. reported solitary node me-
tastasis in the obturator, IIN, parametrial, and common
iliac nodes, mostly (69.2%) in the obturator１９）. Of note,
their results differ from others in the point that no solitary
metastasis was observed in the external iliac nodes,
whereas 3 of 26 solitary metastases were present in the
IIN. Perhaps, these results could be affected by the
equivocal definition of the IIN per the JSCO classifica-
tion, defined as “located in the triangular between the ex-
ternal and internal iliac blood vessels”, whereas the exter-
nal iliac node is defined as “located below the origin of
the external iliac blood vessels”１８）. In our study, we clas-
sified nodes located along the external iliac vein as the
external iliac node, even if these were located between
the external iliac vein and the internal iliac artery. In their
book, Morrow et al. described that “ The hypogastric
lymph nodes although seldom involved in early cervical
cancer, are at risk and frequently involved when there are
multiple nodal metastases ”１６）. The term “ hypogastric
node” is identical to the entire IIN, although some studies
have used this term to designate the most cephalic of the
IIN２０）. This study is entirely consistent with Morrow’s
statement. On the basis of previously reported results and
our data, we anticipate that the retroperitoneal lymphatic
spread in cervical cancer might have, at least, two routes
as follows: (1) the first stream, the major one, flows later-
ally into the obturator nodes and external iliac nodes and
(2) the second stream flows medially into the IIN and
sacral nodes. In the last decade, sentinel lymph node bi-
opsy (SLNB) in cervical cancer has been assessed as a
reliable strategy for identifying patients with negative
pelvic lymph nodes to spare the morbidity related to pel-
vic lymphadenectomy２１）. Perhaps, lymphatic mapping
techniques used in SLNB might be useful for providing
the definitive evidence of the retroperitoneal lymphatic
spread in cervical cancer.
Höckel et al. reported their modified radical hysterec-
tomy based on the ontogenetic anatomy, namely, total
mesometrial resection, and the therapeutic lymph node
dissection６）. We attribute the excellent pelvic control and
PFS (5-year: 81%) by surgery without adjuvant radio-
therapy for patients with node-positive cervical cancer to
their therapeutic lymph node dissection. Our study dem-
onstrates comparable survival outcome of node-positive
patients receiving adjuvant chemotherapy, especially for
patients with squamous cell type. The Japanese Gyne-
cologic Oncology Group ( JGOG) 1070 s retrospective
study compared the outcome of patients with node-
positive cervical cancer who received adjuvant chemo-
therapy and those who received adjuvant CCRT１１）. The 2-
year PFS for the former group was 55.5% and signifi-
cantly lower than not only that of the latter group
(73.9%) but also the reported outcome for node-positive
patients with adjuvant chemotherapy in the other studies
or our study results５）-１０）. The JGOG 1070s study is unique
for that the survey collected 10 consecutive cases per in-
stitute from JGOG-designated institutions, implying that
the results might not reflect the power of teaching or spe-
cialist hospitals. We speculate that one possible factor for
the inferiority of the treatment outcome in the study is the
quality of surgeries, including therapeutic lymphadenec-
tomy such as IIN dissection, although there are no reli-
able documents, which demonstrate the outcome of pa-
tients with cervical cancer who underwent radical hyster-
ectomy without IIN dissection specifically.
Regarding our study, we cannot explicitly state the
therapeutic role of IIN dissection because of the small
number of cases. However, the 2 of the 5 IIN-positive pa-
tients who relapsed had cervical adenocarcinoma (muci-
nous histology). Takeshima et al. reported the results of
adjuvant chemotherapy for node-positive cervical adeno-
carcinoma and inferred that the efficacy of chemotherapy
alone in node-positive cervical adenocarcinoma was not
as high as that in squamous cell type２２）. The remaining 3
IIN-positive patients ( squamous- or adenosquamous-
19
―19―
type) in our study have not experienced relapses to date.
Thus, perhaps, the complete regional node dissection, in-
cluding the IIN, in radical hysterectomy might result in
adequate local control and survival benefit without adju-
vant radiotherapy, at least, in squamous cell type cervical
cancer when combined with adjuvant chemotherapy.
Currently, the JGOG is planning a prospective random-
ized study to compare postoperative chemotherapy and
CCRT in surgically treated high-risk early-stage cervical
cancer, including node-positive patients. Assumedly, this
trial might provide the evidence for the efficacy of adju-
vant chemotherapy in node-positive cervical cancer ;
however, rigorous quality control of radical surgery, in-
cluding node dissection, should be mandatory to obtain
reliable evidence, which could change the routine prac-
tice.
This study has several limitations. First, the sample
size is small. A study with a larger sample size might of-
fer more accurate analysis for the distribution pattern of
node metastases. Second, we administered NACT in 6
patients in this study. Panici et al. examined patients with
early-invasive cervical cancer and locally advanced dis-
ease treated with NACT separately１８）Although they de-
duced that the pattern of the lymphatic spread was simi-
lar to each other, the possibility that the number and dis-
tribution of node metastasis were affected by NACT can-
not be excluded. Meanwhile, from the perspective of sur-
gical procedure, quality uniformity of node dissection
was assured because all surgeries in this study were per-
formed by one surgeon.
Conclusion
Given the high prevalence of IIN metastases in patients
with multiple lymph node metastases, the IIN dissection
should be performed in radical hysterectomy. IIN metas-
tasis might be one of the important factors for regional
recurrence, and pelvic lymphadenectomy without the IIN
dissection in radical hysterectomy could be a pitfall for
the surgical treatment of cervical cancer.
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